An Arizona physician group will pay $4.75 million to resolve allegations that doctors violated the False Claims Act by ...

Background Endovascular therapy (EVT) is standard treatment for large vessel occlusion in patients with a National Institutes ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs ...

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...

D-dimer testing is useful for excluding venous thromboembolism (VTE), where a low D-dimer level helps exclude deep vein thrombosis (DVT) and pulmonary embolism (PE).[1][1] However, elevated levels are ...

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...